UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant to Rule13a-16 or15d-16
of the Securities Exchange Act of 1934
For the month of March 2018
Commission File Number001-38079
UROGEN PHARMA LTD.
(Translation of registrant’s name into English)
9 Ha’Ta’asiya Street
Ra’anana 4365007, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
On March 13, 2018, Dr. Pini Orbach, a director and member of the audit committee of UroGen Pharma Ltd. (the “Company”), resigned from the board of directors of the Company. Dr. Orbach’s decision to resign was not the result of any disagreement with the Company.
On March 15, 2018, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form6-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | |
| | | | UROGEN PHARMA LTD. |
| | | |
| March 15, 2018 | | | | By: | | /s/ Gary S. Titus |
| | | | | | Gary S. Titus |
| | | | | | Chief Financial Officer |
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release, dated March 15, 2018: UroGen Reports Fourth Quarter and Full Year 2017 Financial Results |
